Ziresovir reduces the severity of respiratory syncytial virus in hospitalized infants
1. Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and symptoms of hospitalized young children with RSV infection. 2. The incidence of adverse events was similar between ziresovir and placebo....